Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder
Status:
Not yet recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine if patients with comorbid psychotic disorder and
substance use disorder will continue in treatment longer if treated with clozapine than with
olanzapine, and will have greater reductions in psychosis and in substance use if treated
with clozapine than treated with olanzapine. The specific aims and hypotheses of this trial
are: 1. To compare the enduring effectiveness and tolerability of clozapine and olanzapine,
as measured by time to all-cause treatment discontinuation, over 12 weeks of follow-up; The
investigators hypothesize that patients assigned to clozapine treatment will have
significantly longer times to all cause treatment discontinuation, 2. To compare the total
psychosis items scores between patients treated with clozapine and patients treated with
olanzapine over 12 weeks of follow-up; The investigators hypothesize that patients treated
with clozapine will have significantly lower total psychosis items scores than patients
treated with olanzapine, and 3. To compare the frequencies of positive urine drug screens and
blood alcohol levels (obtained weekly throughout 12 weeks of follow-up) between patients
treated with clozapine and patients treated with olanzapine; The investigators hypothesize
that patients treated with clozapine will have significantly fewer positive urine drug
screens and blood alcohol levels than patients treated with olanzapine.